ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Oral Presentation
Chairs: L. Bjermer (Lund, Sweden), R. Gosens (Groningen, Netherlands)

Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI). P. Daley-Yates (Greenford, United Kingdom)
A randomized trial of AZD7594 a novel non-steroidal anti-inflammatory drug in asthma patients A. Aggarwal (Wellesley, United States of America)
Molecular evidence of Group 1 innate lymphoid cell activation in the U-BIOPRED cohort S. Pavlidis (London, United Kingdom)
MUC5AC expression decrease correlates with the decline in rates of severe asthma exacerbations post bronchial thermoplasty J. Chakir (Québec, QC, Canada)
Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma G. Marchini (Parma, Italy)
Pharmacological properties of novel LTC4 synthase inhibitor P. Glader (Mölndal, Sweden)
Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. F. Roncon Santana (Diadema, Brazil)
Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism R. Saunders (Leicester, United Kingdom)